Randomised controlled trial on GLP-1 agonists in acute pulmonary embolism with insulin resistance and obesity: a proof-of-concept study.

A pulmonary embolism — a blood clot in the lungs — is a serious and potentially life-threatening condition. Current treatment focuses on blood thinners (anticoagulants), but some clots persist despite adequate treatment. Researchers believe that inflammation within the blood vessel walls may be a key reason why some clots do not resolve properly. GLP-1 agonists, a class of medication originally developed for diabetes (like the once-daily injection Liraglutide), have strong anti-inflammatory properties that might help. This proof-of-concept trial is testing whether adding Liraglutide to standard blood-thinner treatment in hospitalised patients with acute pulmonary embolism affects how well the clot resolves and how the heart recovers. It is a randomised, controlled study — meaning some participants will receive Liraglutide and some will receive standard care alone, chosen by chance. You may be eligible if you are 18 or older, have been hospitalised with an acute intermediate or high-risk pulmonary embolism, have already been started on blood-thinning treatment, and have evidence of right-sided heart strain on admission. People with serious heart or lung disease, or who are already taking GLP-1 medications, insulin, or sulfonylureas for diabetes, are not eligible.